Respiratory Tract Infection

NOW ENROLLING: A NEW STUDY OF A 5 DAY DOSE OF INVESTIGATIONAL ORAL MEDICATION FOR THE TREATMENT OF COLD AND FLU -LIKE SYMPTOMS CAUSED BY RESPIRATORY SYNCYTIAL VIRUS (RSV)

Lakeland Clinical Trials is conducting a clinical trial to investigate a new medication for RSV

You may be eligible to participate if:

  • Have experienced up to 48 hours of cold/flu-like symptoms with at least one of the following: Nasal discharge, nasal congestion, malaise/tiredness, headache, sinus congestion, sneezing, sore throat, hoarseness, cough, shortness of breath, respiratory wheeze, earache, and/or symptoms of fever.
  • You are aged 18-75 years old
  • Are not in need of hospitalisation or emergency care.

The study will compare the active study drug to placebo (a 'dummy' medication).

One person in two will receive the placebo and one people in two will receive active study drug. This will be decided randomly and participants will not know which of these they receive during the study.

This trial is currently enrolling. If you are interested please apply via the 'APPLY TO PARTICIPATE' button.

Project Data

SPONSOR

ENANTA Pharmaceuticals 

Apply to Participate

Learn how you could participate in a research study of an investigational drug for reducing the frequency of respiratory tract infections.

Are you at risk of  developing a respiratory tract infection?

The results of this study will provide more information about the investigational drug and whether it could help prevent RTIs.

Who is eligible to participate in this study?

To pre-qualify for this study, you must be: 65 years of age or older and NOT have any of the following:

  • COPD
  • Emphysema
  • Type 1 diabetes mellitus
  • Chronic heart failure
  • Autoimmune disease, such as rheumatoid arthritis
  • Current smoker

All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related travel may be provided.

What will happen during this study?

If you are eligible for this study and you agree to participate, you will be randomly assigned (like flipping a coin) to receive either the investigational drug or placebo (like a sugar pill). You have an equal chance of receiving either one. 

You will take your assigned study drug once a day for 16 weeks. Your total study participation will last about 6 months, which includes approximately 10 visits to the research office for tests and evaluations. There may be more visits required if you have a respiratory tract infection. There will be a follow up phone call about 1 year after you start in the study to ask some questions about your health.

What are the benefits and risks related to this study?

While you could benefit from participating in this study, that cannot be guaranteed. However, your participation may help elderly people in the future.

It is also possible you could experience a side effect during this study. Before you join the study, the study staff will review the full list of known risks and side effects with you.

Because research studies can affect the health of participants, you will be monitored closely while you are in this study. The sponsor of this study was required to design a protocol, which explains all study procedures in detail. An independent review board responsible for participant safety reviewed this protocol and requires that it be followed exactly.

If you would like to learn more about this study, please contact the study team via our application form.

 

Project Data

SPONSOR

PROTECTOR

Apply to Participate

Subscribe to RSS - Respiratory Tract Infection